The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).
Robert I. Haddad(Georgetown University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Joseph I. Clark(Loyola University Medical Center), Sewanti Limaye(Dana-Farber Cancer Institute), Guilherme Rabinowits(Baptist Hospital of Miami), Fadlo R. Khuri(American University of Beirut Medical Center), Douglas R. Adkins(Washington University in St. Louis), Roy B. Tishler(Dana-Farber Cancer Institute), Sarah Riley(Dana-Farber Cancer Institute), Jochen H. Lorch(Northwestern University), Anne O’Neill(International Breast Cancer Study Group), Lori J. Wirth(Massachusetts General Hospital)
Cited by 44
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926